Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
2001 1
2009 1
2011 1
2015 1
2016 1
2017 3
2018 3
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "DS Stage III Plasma Cell Myeloma"
Page 1
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M. Usmani SZ, et al. Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3. Lancet Oncol. 2022. PMID: 34871550 Clinical Trial.
BACKGROUND: Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory multiple myeloma, especially in those previously exposed or refractory to lenalidomide. ...INTERPRETATION: A clear, maintained p …
BACKGROUND: Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory …
Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H. Liu F, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35545345 Free PMC article. Chinese, English.
International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, and 93 cases (17.6%) were missing. ...International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, …
International Staging System (ISS) stage I, II, and III were 10.4%, 24.4%, and 47.6%, respectively, and 93 cases (17.6% …
Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A, Mlak R, Mielnik M, Mazurek M, Chocholska S, Podgajna M, Szczyrek M, Homa-Mlak I, Małecka-Massalska T, Hus M. Szudy-Szczyrek A, et al. Cells. 2022 Feb 21;11(4):752. doi: 10.3390/cells11040752. Cells. 2022. PMID: 35203396 Free PMC article.
MiRNA-8074 is a molecule with the potential to regulate the expression of key genes related to the pathogenesis of multiple myeloma (MM), i.e., TP53, MYC, MAPK1, and KIAA. We analyzed the predictive and prognostic value of miRNA-8074 expression in MM patients. ...In …
MiRNA-8074 is a molecule with the potential to regulate the expression of key genes related to the pathogenesis of multiple myelom …
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P. Rodon P, et al. Eur J Haematol. 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. Eur J Haematol. 2001. PMID: 11168502 Review.
Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 unselected patients with MM aged 75 yr or more at diagnosis. ...Treatment toxicity was mild. Median survival was 22 months. Durie-Salmon ( …
Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 u …
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D. Xu J, et al. Cell Physiol Biochem. 2018;45(4):1631-1640. doi: 10.1159/000487730. Epub 2018 Feb 21. Cell Physiol Biochem. 2018. PMID: 29486474 Free article.
Previous studies showed high expression of CEACAM1 in multiple myeloma (MM). The aim of this study was to investigate the biological consequences of CEACAM1 overexpression in MM. ...CEACAM1 expression in patients with DS stage I was more frequent (61.5 …
Previous studies showed high expression of CEACAM1 in multiple myeloma (MM). The aim of this study was to investigate the biol …
The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
Lu SY, Ma MC, Wang MC, Hsue SS. Lu SY, et al. J Formos Med Assoc. 2021 Nov;120(11):1967-1976. doi: 10.1016/j.jfma.2021.01.015. Epub 2021 Feb 4. J Formos Med Assoc. 2021. PMID: 33551311 Free article.
BACKGROUND/PURPOSE: Myeloma jaw lesions are not uncommon. The study aimed to investigate the status of jaw lesions and medication-related osteonecrosis of jaw (MRONJ) in multiple myeloma (MM) patients. ...RESULTS: Median age of the patients was 67.8 years, an …
BACKGROUND/PURPOSE: Myeloma jaw lesions are not uncommon. The study aimed to investigate the status of jaw lesions and medication-rel …
Association of Growth Differentiation Factor-15 Polymorphisms and Growth Differentiation Factor-15 Serum Levels with Susceptibility to Multiple Myeloma in a Chinese Population.
Li R, Hu Z, Chen H, Lu Y, Qin S, Huang C, Yao Y, Qin X, Wang C. Li R, et al. Clin Lab. 2021 Jan 1;67(1). doi: 10.7754/Clin.Lab.2020.200341. Clin Lab. 2021. PMID: 33491432
BACKGROUND: The aim of our study was to evaluate the relationship between growth differentiation factor-15 (GDF15) rs1058587, rs4808793, and rs1059369 polymorphisms, serum concentrations of GDF15, and International Staging System (ISS) staging or Durie-Salmon sta …
BACKGROUND: The aim of our study was to evaluate the relationship between growth differentiation factor-15 (GDF15) rs1058587, rs4808793, and …
Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, Meng H. Qian J, et al. Hematology. 2017 Sep;22(8):472-476. doi: 10.1080/10245332.2017.1309493. Epub 2017 May 2. Hematology. 2017. PMID: 28463078
OBJECTIVE: This study aims to explore the clinical features of multiple myeloma (MM) and the influence of various prognostic factors on survival. ...IgG was the most common type (46.6%). 52.2% of the patients were diagnosed on stage IIIA according to Durie-Sa …
OBJECTIVE: This study aims to explore the clinical features of multiple myeloma (MM) and the influence of various prognostic f …
The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems.
Scudla V, Pika T, Budikova M, Petrova P, Bacovsky J, Srovnalik K, Minarik J, Langova K. Scudla V, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Dec;153(4):275-82. doi: 10.5507/bp.2009.046. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009. PMID: 20208967
BACKGROUND: The aim of the present paper was to examine the correlation between serum concentrations of 12 soluble biological markers and stages of myeloma evaluated according to the Durie-Salmon (D-S) and International Prognostic Index (IPI) stratification systems. …
BACKGROUND: The aim of the present paper was to examine the correlation between serum concentrations of 12 soluble biological markers and …
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Nanni C, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29270787 Clinical Trial.
: FDG PET/CT ((18)F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. ...Median patie …
: FDG PET/CT ((18)F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myel …
14 results